Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ)

Core Viewpoint - Protagonist Therapeutics (NASDAQ:PTGX) shares fell by 5% following reports that Johnson & Johnson (NYSE:JNJ) may offer a lower takeover price than the current share price [5]. Group 1 - The potential acquisition by Johnson & Johnson is being facilitated by Blackstone, a private equity firm [5].